The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Novartis announced on May 5, 2022, a "temporary, voluntary suspension of production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey." The Company halted production to "address potential quality issues identified in its manufacturing process." Based on this news, shares of Novartis fell 2.3% on the same day. STAT News published an article on May 31, 2022, titled: "Documents show problems at Novartis facility where cancer drug production was halted." According to the article, the FDA cited the Company for deficiencies after a 2021 inspection including "concern that Novartis failed to notify customers about batches of Lutathera . . . that were distributed despite failing to meet quality specifications." Based on this news, shares of Novartis fell by 1.99% across the next two trading sessions.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220715005327/en/